Immutep Ltd
immutep.comWhat Do They Do?
Develops drug candidates that use immune-system pathways to treat cancer and autoimmune disease, including eftilagimod alfa for cancer and a candidate for autoimmune disease.
20-F for FY2026, filed Oct 23, 2026Immutep is a late-stage biotechnology company developing novel LAG-3 related immunotherapies for cancer and autoimmune disease. We are…View ↗
Our lead clinical candidate is eftilagimod alfa (“efti” or “IMP321”) for the treatment of different types of cancers. Efti is a soluble…View ↗
IMP701 (LAG525; INN: ieramilimab) was licensed to CoStim Pharmaceuticals, which was subsequently acquired by Novartis. In August 2026, the…View ↗
Who Are Their Customers?
Pharmaceutical partners license rights to develop drug candidates, and other researchers buy LAG-3 materials for further studies.
20-F for FY2026, filed Oct 23, 2026At present, the Group is in the research and development phase of operations and license revenue earned is through milestone payments by…View ↗
Income from the sale of materials supplied to other researchers in order to conduct further studies onView ↗
LAG-3View ↗
technologies is recognized at a point in time when the materials are delivered, the legal title has passed, and the other party has…View ↗
How Are They Changing?
Efti trial stopped
The older report said Immutep was preparing to start a late-stage efti trial in lung cancer; the latest says the study was stopped after an interim analysis and is being wound down.
20-F for FY2023, filed Oct 24, 2023 20-F for FY2026, filed Oct 23, 2026As part of the Company’s late-stage clinical development strategy for Efti, Immutep is preparing to commence TACTI-004 which is a…View ↗
In March 2026, following a planned interim futility analysis, Immutep discontinued TACTI-004 (NCT06726265; KEYNOTE-F91), its registrational…View ↗
Efti licensing
The older report described efti as being developed through Immutep’s clinical trials; the latest adds an exclusive agreement giving Dr. Reddy’s rights to develop and commercialize it outside Immutep’s territory.
20-F for FY2023, filed Oct 24, 2023 20-F for FY2026, filed Oct 23, 2026As part of the Company’s late-stage clinical development strategy for Efti, Immutep is preparing to commence TACTI-004 which is a…View ↗
During fiscal 2026, Immutep also entered into a strategic licensing agreement with Dr. Reddy’s Laboratories (Dr. Reddy’s), granting Dr.…View ↗
Partnered assets return
The older report described candidates licensed to pharmaceutical partners; the latest says Novartis ended its agreement and Immutep is taking the asset back, while a separate asset had returned.
20-F for FY2023, filed Oct 24, 2023 20-F for FY2026, filed Oct 23, 2026Two LAG-3 product candidates (IMP701 and IMP731) including antibodies for immune response modulation in autoimmunity and cancer are…View ↗
IMP701 (LAG525; INN: ieramilimab) was licensed to CoStim Pharmaceuticals, which was subsequently acquired by Novartis. In August 2026, the…View ↗
Loading...
